Abstract 216P
Aim/Background
Hepatitis B virus (HBV) is a major public health problem, and Hepatitis B virus-related hepatocelular carcinoma (HBV-HCC) has an extremely poor prognosis due to a lack of effective treatments. B7-H4 is a novel member of the B7 superfamily that are actively involved in regulating the pathogenesis of tumors. However, the intrahepatic expression of B7-H4 in HBV-HCC patients has not been described. In this study, we investigated the expression and clinical significance of B7-H4 and Hepatitis B Virus X (HBx) protein in HBV-HCC.
Methods
The expression of B7-H4 in the human HCC cell lines HepG2 and HepG2215 was detected by western blotting, flow cytometry and immunofluorescence analysis. The expression of B7-H4 and HBx in 83 HBV-HCC was detected by immunohistochemistry, and the relationship with clinicopathological features was analyzed.
Results
B7-H4 was significantly up regulated in HepG2215 cells than in HepG2 cells. The positive rates of B7-H4 and HBx in 83 HBV-HCC tissues were 68.67%(57/83)and 59.04%(49/83) respectively. The expression of HBx was correlated with TNM staging. The expression of B7-H4 was positive correlated with HBx (rs = 0.388, P < 0.01). The expression level of B7-H4 in HBx-positive HBV-HCC tissues was substantially higher than that in HBx-negative HBV-HCC tissues, which was negative related to tumor TNM stage.
Conclusions
The higher expression of HBx and B7-H4 were correlated with tumor progression of HBV related hepatocelular carcinoma. B7-H4 may be an effect molecule in HBV related hepatocarcinogenesis.
Clinical trial identification
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Vitamin D3 (cholecalciferol) acts as a negative regulator of breast cancer cell invasiveness in the absence of activation of classical VDR signalling
Presenter: MD Musharraf Hossain
Session: Poster presentation 1
Resources:
Abstract
VCP/p97 inhibition is a therapeutic strategy to overcome drug resistance in ovarian and pancreatic cancers
Presenter: Yuliana Astuti
Session: Poster presentation 1
Resources:
Abstract
Upregulation of the interleukin 17/granulocyte-colony stimulating factor/fibroblast growth factor axis and its correlation with indoleamine 2,3-dioxygenase in breast cancer
Presenter: Kosuke Kawaguchi
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
Presenter: Ayumu Hosokawa
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Presenter: Yoshito Komatsu
Session: Poster presentation 1
Resources:
Abstract
Tuberculosis exposure and the risk of cancer
Presenter: Vincent Yi-Fong Su
Session: Poster presentation 1
Resources:
Abstract
Triple negative breast cancer and androgen receptor expression: a forerunner for a novel hormonal approach
Presenter: Prameela Chelakkot G
Session: Poster presentation 1
Resources:
Abstract
Treatment of radiation induced side-effects in prostate cancer patients with hyperbaric oxygen therapy
Presenter: HAYATO Takeda
Session: Poster presentation 1
Resources:
Abstract
Tolerability and efficacy of neoadjuvant chemotherapy with three-weekly interval methotrexate, doxorubicin, vinblastine and cisplatin regimen for patients with locally advanced bladder cancer
Presenter: Satoko Arai
Session: Poster presentation 1
Resources:
Abstract
To compare the efficacy and safety of pazopanib and sunitinib in metastatic renal cell carcinoma (RCC) of Chinese population
Presenter: Michelle Fong Ting Chan
Session: Poster presentation 1
Resources:
Abstract